Compare Costco Wholesale Corporation (COST) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Costco Wholesale Corporation vs Viatris Inc — how do they compare? Costco Wholesale Corporation trades at $944.18 (market cap $420.05B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Costco Wholesale Corporation is far larger — about 21× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold Costco Wholesale Corporation for 132 Days and Viatris Inc for 57 Days on average.
| COST | VTRS | |
|---|---|---|
Market Cap | $420.05B | $20.03B |
Volume | 2,087,565 | 14,109,977 |
Sector | Consumer Staples | Health |
52-Week High | $1.09K | $18.27 |
52-Week Low | $849.63 | $9.74 |
Typical Hold Time | 132 Days | 57 Days |
Enterprise Value | $407.33B | $32.15B |
Dividend Yield | 0.62% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COST trades at $944.20, up 0.21% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong March 2026 sales growth of 11.3% year-over-year (Costco Wholesale Corporation, April 8, 2026) and has shown consistent revenue and net income growth, with fiscal 2025 revenue at $275.24B and net income at $8.10B. Analyst consensus is strongly bullish with a $1,100 price target, though valuation ratios like a P/E of 45.66 are elevated.
The outlook remains positive due to robust membership fee growth and expansion, but risks include high valuation sensitivity and competitive pressures. Upside is supported by strong institutional buying and earnings beats, though any market pullback could pressure the stock given its premium multiples.
Viatris (VTRS) trades at $17.625, up 0.77% with a bullish technical signal. The company shows mixed fundamentals with declining revenue from $16.3B in 2022 to $14.3B in 2025 and negative net income margins, though recent quarters have beaten EPS estimates. Positive cash flow trends and a $0.12 dividend signal financial stability. Analyst consensus is mixed with 38% buy ratings and a $22.17 price target suggesting 26% upside.
The outlook balances operational strength against profitability challenges. Investment appeal lies in value metrics (P/S 1.38), consistent earnings beats, and dividend yield, but risks include sustained negative margins, high debt, and competitive pressures. The stock's re-rating depends on margin improvement and pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
